Lilly moves Crohn’s drug into phase 3, faces safety setback in JapanEli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab, Share XLilly moves Crohn’s drug into phase 3, faces safety setback in Japanhttps://pharmaphorum.com/news/lilly-moves-crohns-drug-mirikizumab/
Amgen offers $167m for drug discovery biotech NuevolutionAmgen has agreed to buy Swedish biotech Nuevolution for around $167 million to boost its drug pipeline after Share XAmgen offers $167m for drug discovery biotech Nuevolutionhttps://pharmaphorum.com/news/amgen-offers-167m-for-drug-discovery-biotech-nuevolution/
AI system beats radiologists at predicting lung cancer riskA deep learning AI system was able to detect malignant lung nodules better than radiologists in a new Share XAI system beats radiologists at predicting lung cancer riskhttps://pharmaphorum.com/news/ai-system-beats-radiologists-at-predicting-lung-cancer-risk/
Merck & Co to buy cancer biotech Peloton for $2.2bnMerck & Co is to buy the privately-held biotech Peloton for up to $2.2 billion, adding further oncology Share XMerck & Co to buy cancer biotech Peloton for $2.2bnhttps://pharmaphorum.com/news/merck-co-to-buy-cancer-biotech-peloton-for-2-2bn/
UDG Healthcare acquires Putnam Associates and Incisive HealthUDG Healthcare has boosted its Ashfield Communications and Advisory business with a brace of deals, acquiring Putnam Associates Share XUDG Healthcare acquires Putnam Associates and Incisive Healthhttps://pharmaphorum.com/news/udg-healthcare-putnam-incisive-health/
Verily signs up four big pharmas to its clinical trials platformVerily, the life sciences company owned by Google parent Alphabet, has teamed up with Novartis, Sanofi, Otsuka, and Share XVerily signs up four big pharmas to its clinical trials platformhttps://pharmaphorum.com/news/verily-signs-up-four-big-pharmas-to-its-clinical-trials-platform/
Merck & Co’s Keytruda fails in triple negative breast cancer trialMost of the time, Merck & Co’s Keytruda (pembrolizumab) has been a consistent performer across a range of Share XMerck & Co’s Keytruda fails in triple negative breast cancer trialhttps://pharmaphorum.com/news/merck-cos-keytruda-fails-in-triple-negative-breast-cancer-trial/
UK’s LifeArc charity nets $1.3 billion Keytruda windfallThe UK’s medical research charity LifeArc has received a windfall of nearly $1.3 billion after selling a portion Share XUK’s LifeArc charity nets $1.3 billion Keytruda windfallhttps://pharmaphorum.com/news/uks-lifearc-charity-nets-1-3-billion-keytruda-windfall/
Amryt to expand rare disease portfolio with $311m Aegerion mergerRare disease specialist Amryt Pharma plans to expand its rare disease portfolio with the acquisition of troubled Aegerion Share XAmryt to expand rare disease portfolio with $311m Aegerion mergerhttps://pharmaphorum.com/news/amryt-to-expand-rare-disease-portfolio-with-311m-aegerion-merger/
